Tissue Testing Technologies
Tissue Testing Technologies LLC (T3) was a private North Charleston biotech firm developing biopreservation technology to extend organ, tissue, and cell viability for transplantation centers and therapeutic applications. It was acquired by LifeNet Health on December 15, 2025.
- Company typePrivate
- Founded2014
- HeadquartersNorth Charleston, United States
- Headcount—
- GTM typeB2B
- OfferingServices
What Tissue Testing Technologies does
Tissue Testing Technologies LLC (also operating under the name "T3") was a private biotechnology company founded in 2014 and based in North Charleston, United States. The company specialized in biopreservation technology focused on extending the viability of organs, tissues, and cells outside the body for use in transplantation and therapeutic applications. Its core technology addressed a fundamental constraint in transplant medicine — the short preservation window for biological materials — and was positioned to serve healthcare providers, specifically transplant centers, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications.
No specific named products, pricing models, distribution channels, management team members, funding rounds, patents, certifications, or AI capabilities were disclosed in available sources. The company's public website remained in a "Coming Soon" placeholder state, indicating either limited commercial deployment or an early-stage commercial profile prior to the acquisition. The company's overall visibility in public data sources is low, consistent with a small private biotech operating in a specialized niche.
On December 15, 2025, Tissue Testing Technologies was acquired by LifeNet Health, a strategic operating company in the regenerative medicine sector. The acquisition transferred T3's biopreservation capabilities into LifeNet Health's broader portfolio, with stated rationale of improving organ and tissue preservation and extending therapeutic opportunities. Following the acquisition, Tissue Testing Technologies ceased to operate as an independent entity and is now a subsidiary under LifeNet Health's ownership.
Tissue Testing Technologies firmographics
Firmographics- Name
- Tissue Testing Technologies
- Legal name
- Tissue Testing Technologies LLC
- Website
- https://tissuetestingtech.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Short description
- Tissue Testing Technologies LLC (T3) was a private North Charleston biotech firm developing biopreservation technology to extend organ, tissue, and cell viability for transplantation centers and therapeutic applications. It was acquired by LifeNet Health on December 15, 2025.
- Ownership category
- akta.pro rank
Tissue Testing Technologies industry classification
Industry- Product category
- Tissue Biopreservation
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (541380), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability) (HLAAABAK)
Keywords
Where Tissue Testing Technologies is headquartered
LocationHeadquarters
- HQ city
- North Charleston
- HQ country
- United States
- HQ region
- North America
Markets served
Tissue Testing Technologies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Tissue Testing Technologies product offering
Product offeringCore offering
Tissue Testing Technologies LLC (T3) is a biotechnology firm that develops biopreservation technology focused on organ and tissue preservation. The company provides preservation solutions for research purposes, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications. The company was acquired by LifeNet Health on December 15, 2025.
Product overview
Tissue Testing Technologies LLC (T3) was a biotech company specializing in biopreservation technology. The company was acquired by LifeNet Health on December 15, 2025. No specific named products, modules, or service offerings were identified in the available source data.
Differentiator
Problem solved
Functional benefit
Companies that use Tissue Testing Technologies
Customer profileSegments1 record
Ideal customer profiles1 record
Tissue Testing Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tissue Testing Technologies partnerships and signals
Strategic signalScale indicators1 record
Recent moves1 record
Expansion highlights2 records
Tissue Testing Technologies competitors and assessment
Company assessmentBroad incumbents
- MTF Biologics: MTF Biologics is a major tissue bank and regenerative-medicine organization distributing allograft tissues — broad incumbent serving overlapping end markets (transplant and therapeutic use of preserved biological materials).
- LifeNet Health: LifeNet Health is T3's acquirer and the largest nonprofit organ-procurement and tissue-banking organization in the U.S. — broad incumbent that now owns T3's biopreservation capabilities and serves the same transplant-center customer base.
Direct peers
- Organ Recovery Systems: Organ Recovery Systems (now part of global transplant solutions) provides Lifeport kidney perfusion machines and preservation fluids — direct peer in perfusion-based organ preservation technology and transplant-center delivery.
- XIVIO Perfusion: XIVIO develops machine perfusion and preservation solutions for kidneys, livers, and lungs — comparable biopreservation technology serving the same transplant-center workflows as T3.
- TransMedics: TransMedics offers the Organ Care System for heart, lung, and liver preservation, competing head-to-head in extending ex-vivo organ viability for transplantation — same customer segment and use case as T3.
- BioLife Solutions: BioLife Solutions provides biopreservation media, storage, and shipping products (CryoStor, HypoThermosol) for cells and tissues — directly comparable preservation technology with overlap in cell/tissue therapy storage.
- Bridge to Life: Bridge to Life supplies preservation solutions and perfusion devices for organ and tissue transplantation — directly overlapping with T3's preservation/transport offering for transplant centers.
- OrganOx: OrganOx develops normothermic machine perfusion platforms (e.g., metra) for liver and kidney preservation — directly comparable to T3's biopreservation/organ-viability mission and the same transplant-center customer base.
- Paragonix Technologies: Paragonix provides hypothermic organ preservation and transport devices (SherpaPak, LungGuard) — a direct competitor to T3 in extending organ viability windows and serving transplant centers.
Emerging players
- Vitanova Biomedical: Vitanova Biomedical works on tissue and organ preservation technologies targeting improved viability for transplant and regenerative medicine — adjacent niche player with partial overlap to T3's biopreservation focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks4 records
Key highlights4 records
Customer concentration
Tissue Testing Technologies social profiles
Digital presenceTissue Testing Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tissue Testing Technologies leadership team
Management profileNumber of profiles
Tissue Testing Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tissue Testing Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tissue Testing Technologies
What does Tissue Testing Technologies do?
Tissue Testing Technologies LLC (T3) is a biotechnology firm that develops biopreservation technology focused on organ and tissue preservation. The company provides preservation solutions for research purposes, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications. The company was acquired by LifeNet Health on December 15, 2025.
When was Tissue Testing Technologies founded?
Tissue Testing Technologies was founded in 2014.
Where is Tissue Testing Technologies based?
Tissue Testing Technologies is headquartered in North Charleston, United States, in the North America region.
Who are Tissue Testing Technologies's main competitors?
Broad incumbents on record are MTF Biologics and LifeNet Health. Direct peers are Organ Recovery Systems, XIVIO Perfusion, TransMedics, BioLife Solutions, Bridge to Life, OrganOx and Paragonix Technologies. Vitanova Biomedical is listed as an emerging player.
Does Tissue Testing Technologies have an API?
No public API is recorded for Tissue Testing Technologies.
What industry is Tissue Testing Technologies in?
Tissue Testing Technologies's product category is Tissue Biopreservation. Its primary akta.pro industry code is HLAAABAK, Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability). Its NAICS code is 541714 and its SIC code is 8731.